PFAS Testing Expansion The company launched a testing method for ultrashort-chain PFAS, indicating a capability to address advanced environmental analytics. This presents sales opportunities with clients requiring cutting-edge contaminant detection and regulatory compliance in water and environmental programs.

Strategic Partnerships Partnership with Aspire Biolabs to handle drug-excipient compatibility and formulation development signals appetite for collaboration in pharma and biotech sectors, suggesting cross-sell potential into manufacturing, stability studies, and batch manufacturing services.

Regulatory Recognition Receiving an Environmental Business Journal Award for respirable crystalline silica testing demonstrates credibility in compliance-focused testing. This can be leveraged to win new contracts from organizations prioritizing worker safety, OSHA/NAHB projects, and industrial hygiene programs.

Leadership and Capacity Growth Recent leadership appointments and investments in two life sciences laboratories show a commitment to scale capabilities and client service. This indicates readiness to take on larger pharmaceutical and biopharma engagements and expand service offerings.

Industry Footprint Operating in environmental services with a mid-market revenue footprint and a broad tech stack supporting data-driven testing positions the company to compete for mid-to-large enterprise environmental contracts, including NPDES, RCRA, FDA, and Safe Drinking Water programs.